SELECTION AND DETERMINATION OF THE OPTIMAL CONCENTRATION OF THE PLATELET AGGREGATION INDUCER IN INTENSIVE THERAPY OF PATIENTS WITH COVID-19 INFECTION

The change in platelet function that occurs in patients during treatment for a new coronavirus infection can be determined using the platelet aggregation method. Objectives. To determine optimal inducer of platelet aggregation and to assess its prognostic significance in intensive therapy of patients with COVID-19 infection. Material and methods. 34 patients with new coronavirus infection were included in group 1, and 30 healthy women were included in group 2. The study of platelet aggregation was carried out by the turbidimetric method with AP2110 analyzer (SOLAR, Results. The area under the aggregation curve was statistically significantly greater in patients in group 1 when using an ADP inducer at a dose of 0.3 μg/ml (69.1 (27.3; 164.4) unit in comparison with 55.3 (31.5; 68.2) units in group 2, p<0.001). When using an ADP inducer in high concentrations of 1.25 and 2.5 μg/ml and an adrenaline inducer in concentrations of 2.5 and 5 μM, the area under the curve in patients with COVID-19 infection was statistically significantly lower compared to group 2. The area under the aggregation curve according to the Hosmer-Lemeshov criterion has been found to be an independent predictor of death in the intensive care unit (Chi-square=5.074, p=0.06 for ADP 0.3 μg/ml and Chi square=15.121, p=0.057 for ADP 0.6 μg/ml). Conclusions. A comparative analysis of platelet aggregation using inducers of ADP, adrenaline and collagen has shown that in patients with new coronavirus infection, the degree of coagulation imbalance should be determined according to the indications obtained with an ADP inducer at a dose of 0.3 and 0.6 μg/ml.